Notwithstanding promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial resistance from PBMs. The insurers are often creating limitations to reimbursement, like significant price restrictions and prior au